Summary of Jilin Aodong Pharmaceutical Group Conference Call Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1957 and has developed into a holding company with multiple subsidiaries in pharmaceuticals, medical research, and sales, among others [3][4][6] - The company operates under a "pharmaceutical + finance" dual-driven model and has a comprehensive supply chain involving planting and breeding bases [3][4] Key Points from the Conference Call Governance and Operational Efficiency - The company has received multiple governance honors in 2024, including recognition for its board practices, which have contributed to improved operational performance [6] - Continuous improvement of corporate governance structures and internal controls has been emphasized to ensure accurate information disclosure and enhance investor returns [6] Multi-Drive Development Model - The company is focused on a "pharmaceutical + finance + health" multi-drive development model, enhancing synergy and resource sharing across its various segments [7][8] - Marketing strategies have been optimized to align with national pharmaceutical policies, enhancing the efficiency of academic promotion and channel management [8] Market Expansion and Product Development - Jilin Aodong is actively exploring international markets while maintaining steady growth in its pharmaceutical core business [9][10] - The company has optimized its chemical drugs and retail pharmacy businesses, leveraging e-commerce platforms for sales growth [10][11] Financial Performance - In 2024, the company reported a revenue of 2.61 billion yuan, a decrease of 24.31% year-on-year, while net profit increased by 6.27% to 1.55 billion yuan [13][14][36] - The traditional Chinese medicine segment remains the largest contributor, accounting for 61.50% of total revenue [14][31] R&D and Innovation - R&D investment in 2024 was approximately 99.91 million yuan, a decrease of 29.69% from the previous year, with a focus on balancing R&D spending with cost control [32][33] - The company is committed to modernizing traditional Chinese medicine through innovative research and development, particularly in areas like cancer and cardiovascular diseases [33][42] Brand and Market Positioning - The "Aodong" brand has been recognized as a famous Chinese trademark and has a brand value of approximately 11.68 billion yuan [15][16] - The company aims to enhance its market share through targeted marketing strategies and maintaining high product quality [15][43] Challenges and Strategic Responses - The company faces challenges such as industry competition and product homogenization, which it addresses through differentiated marketing strategies and quality management [43] - Plans for 2025 include focusing on core products, optimizing shareholder returns, and enhancing market confidence through effective management practices [38][39] Future Outlook - The company is optimistic about growth in 2025, focusing on expanding its core product lines and enhancing R&D capabilities to meet market demands [41][42] - Jilin Aodong aims to leverage its strengths in traditional Chinese medicine and health products to capture emerging market opportunities [41][42] Additional Important Information - The company has implemented a cash dividend plan for 2024, distributing 3 yuan per 10 shares, balancing shareholder returns with capital needs [20][21] - The first quarter of 2025 saw a revenue of 623 million yuan, a decline of 27.71%, but net profit surged by 259.75% due to investment gains [22][23] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Jilin Aodong's operational strategies, financial performance, and future growth plans.

Core Insights - The company is focusing on expanding its online sales through major e-commerce platforms like JD.com, Taobao, and Pinduoduo, while also enhancing its O2O (Online to Offline) business model to seek new growth points [1] - A new pharmaceutical marketing management center has been established to strengthen professional service capabilities, with measures in place to revitalize slow-moving and unsold products [1] - The company aims to create a closed-loop ecosystem in the pharmaceutical industry by enhancing product supply from its manufacturing segment and improving customer retention through membership and pharmaceutical services [1] Sales and Marketing Strategy - The company is consolidating its market position for key products like injection-grade ribonucleic acid II through a clinical-to-terminal sales model and optimizing performance assessments for clinical personnel [1] - Plans include hosting marketing summits and academic seminars to cover hospital terminals and promote resource coverage nationwide [1] - The company is accelerating market penetration for selected products through centralized procurement and aims to achieve sales growth with newly approved products [2] Research and Development - The company is actively exploring traditional Chinese medicine and conducting research in various therapeutic areas, including cancer, kidney disease, diabetes, and cardiovascular diseases [3] - Multiple generic drug approvals have been obtained, including phosphoric acid oseltamivir capsules and others, indicating a steady progression in R&D projects [3] Technological Integration - The company is leveraging AI technology to optimize drug screening and clinical trial design, moving towards a smart manufacturing model that emphasizes high quality and efficiency [4] - A marketing reform initiative has been launched to establish a unified command and collaborative marketing system, enhancing strategic coordination and operational awareness across the organization [4]

Governance and Management - Jilin Aodong has received multiple governance honors, including the 2024 Excellent Board Practice Case, highlighting its commitment to corporate governance and operational performance improvement [2][3] - The company has established a robust governance structure and internal control management system to ensure accurate and complete information disclosure [2][3] Financial Performance - In 2024, the company achieved a revenue of CNY 261,057.51 million, a decrease of 24.31% compared to the previous year, while net profit attributable to shareholders increased by 6.27% to CNY 155,139.31 million [7][14] - The cost of the pharmaceutical segment decreased by 12.56% year-on-year, indicating effective cost management strategies [6][14] Business Segments - The three main business segments—traditional Chinese medicine, chemical pharmaceuticals, and retail pharmacy—generated a combined revenue of CNY 227,376.10 million, accounting for 87.10% of total revenue [7][11] - The traditional Chinese medicine segment alone contributed CNY 160,554.13 million, representing 61.50% of total revenue [7][9] Marketing and Sales Strategies - The company is enhancing its marketing system by integrating online sales through major e-commerce platforms and optimizing its offline stores for O2O business [5][11] - A focus on core product matrix development and strategic marketing initiatives has been implemented to improve sales performance and market penetration [10][11] Research and Development - In 2024, R&D investment amounted to CNY 99,909,053.79, a decrease of 29.69% from the previous year, with a focus on balancing R&D spending and cost control [17][19] - The company is actively pursuing innovation in traditional Chinese medicine and exploring new product development in various therapeutic areas [19][20] Shareholder Returns - The company plans to distribute a cash dividend of CNY 3 per 10 shares for 2024, reflecting a commitment to shareholder returns while balancing operational needs [12][13] - A three-year shareholder return plan has been established to enhance dividend frequency and optimize payout ratios [12][13] Challenges and Future Outlook - The company faces challenges such as declining revenue and increasing accounts receivable relative to revenue, prompting a focus on risk management and operational efficiency [16][21] - Future strategies include enhancing core product market share, expanding into international markets, and leveraging AI technology for operational improvements [20][21]

北京市京都（大连）律师事务所 法律意见书 北京市京都（大连）律师事务所 关于吉林敖东药业集团股份有限公司 召开 2024 年年度股东大会 之 法 律 意 见 书 致：吉林敖东药业集团股份有限公司 北京市京都（大连）律师事务所（以下简称"本所"）接受吉林敖东药业集团股 份有限公司（以下简称"公司"）的委托，指派本所律师 王秀宏、杨姗姗 出席公司 2024 年年度股东大会（以下称"本次股东大会"）。本所律师根据《中华人民共和国 公司法》（以下简称《公司法》）、中国证监会《上市公司股东会规则》（以下简称 《股东会规则》）和《吉林敖东药业集团股份有限公司章程》（以下简称《公司章程》） 的相关规定，就公司本次股东大会的召集与召开程序、出席会议人员与召集人的资格、 议案的提出、表决程序和结果等事宜的合法性、有效性进行见证并出具法律意见。 公司保证和承诺其已经向本所律师提供了为出具本法律意见书所必需的、真实的 原始书面材料、电子邮件；有关副本材料、复印件与原件一致；公司对所提供的文件 资料的合法性和有效性承担法律责任。 本所律师根据对事实的了解和对法律的理解发表法律意见。 本所及本所律师对所出具的法律意见书承担法律责任。 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-029 吉林敖东药业集团股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会无变更以往股东大会已通过决议的情形。 一、会议召开和出席情况 （一）召开情况 1、会议召开的时间： （1）现场会议召开的时间：2025年5月23日（星期五）下午14:00开始。 （2）网络投票时间： 2、召开地点：吉林省敦化市敖东大街2158号公司办公楼六楼会议室 3、表决方式：现场投票与网络投票相结合的方式 4、召集人：吉林敖东药业集团股份有限公司董事会 5、主持人：董事长李秀林先生 6、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章程》的规定。 （二）出席情况 1、出席现场会议及网络投票的股东及股东授权委托代表合计 509 人，代表 股份数 418,189,662 股，占公司有表决权股份总数 1,172,381,587 股（有表决 权股 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-028 吉林敖东药业集团股份有限公司 特此公告！ 吉林敖东药业集团股份有限公司董事会 2025 年 5 月 20 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，吉林敖东药业集团股份有限公司（以 下简称"公司"）将参加由吉林省证券业协会、深圳市全景网络有限公司共同 举办的"2025年吉林辖区上市公司投资者网上集体接待日活动"，现将有关事 项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演APP，参与本次互动交流。活动时间为2025年5月27日（周二）15:00-16:30。 届时公司副董事长、总经理郭淑芹女士，董事、副总经理杨凯先生，董事、 副总经理、财务总监张淑媛女士，董事、副总经理、董事会秘书王振宇先生， 将在线就公司2024年度业绩、公司治理、发展战略、经营状况等投资者关心的 问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 关于参 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-027 吉林敖东药业集团股份有限公司 关于召开 2024 年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1.吉林敖东药业集团股份有限公司已于2025年4月23日发布《关于召开2024 年度股东大会的通知》（公告编号：2025-023），为进一步保护投资者的合法权 益，方便股东行使股东大会表决权，现发布《关于召开2024年度股东大会的提示 性公告》。 2.本次股东大会采取现场投票与网络投票相结合的方式。 吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会第十 六次会议决议召开公司2024年度股东大会（以下简称"本次股东大会"），本次 股东大会采用现场投票和网络投票相结合的表决方式，现将有关事项通知如下： 一、召开会议基本情况 1.股东大会届次：2024年度股东大会 2.股东大会的召集人：公司董事会 3.会议召开的合法、合规性：经公司第十一届董事会第十六次会议审议通过， 决定召开公司2024年度股东大会，本次股东大会会议召开符合有关法律、行政法 规、 ...

Core Insights - The behavior of margin traders has attracted significant market attention, with investors hoping to capture investment opportunities from their activities [1] Group 1: Margin Trading Data - On May 8, a total of 3,663 stocks received margin buying funds, with the top three stocks being Xinyi Technology (¥1.425 billion), Zhongji Xuchuang (¥1.053 billion), and Shenghong Technology (¥807 million) [1] - The table lists stocks with the highest margin buying amounts, including Tiancheng Technology (¥15.75 million), Xingqiu Graphite (¥8.83 million), and Lianyu Co. (¥15.27 million), showing their respective transaction amounts and margin buying ratios [1] - Margin buying accounted for significant percentages of total transaction amounts for various stocks, with Tiancheng Technology at 28.65%, Xingqiu Graphite at 28.51%, and Lianyu Co. at 28.15% [1] Group 2: Stock Performance - The price changes of stocks with high margin buying varied, with some stocks experiencing gains, such as Tiancheng Technology (1.47%) and Xingqiu Graphite (2.39%), while others like Fuliwang saw a decline (-3.29%) [1][2] - The data indicates that margin buying can correlate with stock performance, as seen in the fluctuations of the stocks listed [1][2]

Business Performance - In 2024, the company's main business segments generated a total revenue of CNY 2,273.76 million, accounting for 87.10% of total revenue, a decrease of 23.79% year-on-year [1] - The breakdown of revenue by segment is as follows: - Traditional Chinese Medicine (TCM): CNY 1,605.54 million (61.50%) - Chemical drugs: CNY 276.85 million (10.61%) - Chain pharmacy wholesale and retail: CNY 391.37 million (14.99%) - Health business: CNY 212.13 million (8.13%) [1] Product Development - The "Xuefu Zhuyu Oral Liquid" is a key product derived from a classic formula, recognized with multiple awards, including the National Science and Technology Progress Award [1] - In 2024, this product was selected for centralized procurement, which is expected to enhance its market share [2] Cost Control Measures - The company is addressing rising costs of herbal materials through several strategies: - Establishing GAP bases for stable supply of key herbs - Utilizing data analysis for demand forecasting and optimizing procurement [3] - Enhancing supply chain management and internal efficiency to reduce costs [3] Chemical Drug Segment - The chemical drug segment achieved a revenue of CNY 276.85 million in 2024, representing 10.61% of total revenue [4] - Key products include anti-tumor and immune-regulating drugs, with significant sales growth in specific items like injection RNA [4][6] - The company is focusing on deep market penetration and academic promotion to expand its market share [6] Retail and Wholesale Business - The chain pharmacy segment generated CNY 391.37 million in revenue, accounting for 14.99% of total revenue [8] - Membership increased by 18,300, totaling 1,189,000 members, with a net addition of 6 stores [8] - The company is enhancing online sales through major e-commerce platforms and implementing O2O strategies [9] Investment and Shareholder Returns - The company holds 20.05% of Guangfa Securities, its largest investment, enhancing its capital position [10] - A cash dividend of CNY 591 million is planned for 2024, reflecting a commitment to shareholder returns while balancing operational needs [12][13]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 □是 √否 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000623 证券简称：吉林敖东 公告编号：2025-025 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ （二） 非经常性损益项目和金额 √适用 □不适用 单位：元 ■ 其他符合非经常性损益定义的损益项目的具体情况 □适用 √不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》中列举的非经常性损益项目界 定为经常性损益项目的情况说明 □适用 √不适用 公司不存在将《公开发行证券的公司信息披露解释性公告 ...